Steps to manage treatment-refractory migraine in adults.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY
Dimos D Mitsikostas, Christina Deligianni, Artemis Mavridi, Victor Gkotzamanis, Theodoros Mavridis
{"title":"Steps to manage treatment-refractory migraine in adults.","authors":"Dimos D Mitsikostas, Christina Deligianni, Artemis Mavridi, Victor Gkotzamanis, Theodoros Mavridis","doi":"10.1080/14737175.2025.2555305","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Refractory migraine (RM) is characterized by a lack of response to both migraine-specific and repurposed treatments, significantly impairing quality of life. Risk factors for RM include, among others, overuse of symptomatic medications, nonadherence to treatment and comorbid conditions that limit the use of anti-migraine medications.</p><p><strong>Areas covered: </strong>This critical perspective addresses the diagnosis and management of patients with RM. It also highlights the best practices tailored to this complex condition, serving as a valuable tool for physicians.</p><p><strong>Expert opinion: </strong>Management demands specialized, holistic approach that considers patient preferences and may deviate from conventional evidence-based practices. Diagnosis requires thorough evaluation to exclude conditions like cluster headaches or trigeminal neuralgias. Treatment integrates symptomatic, interim, and prophylactic strategies. Symptomatic options include triptans, ditans, and gepants, often combined with NSAIDs or antiemetics, but gepants are first-line option because of their low risk for medication overuse headache. Interim treatments, intended to bridge to prophylactic therapy, might involve steroids or long acting triptans. Prophylactic treatments favor migraine-specific medications due to their superior tolerability and effectiveness. Non-pharmacological approaches are also encouraged while continuous monitoring and reassessment after initial treatments are essential, recognizing that RM may recur after a temporary improvement phase.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2025.2555305","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Refractory migraine (RM) is characterized by a lack of response to both migraine-specific and repurposed treatments, significantly impairing quality of life. Risk factors for RM include, among others, overuse of symptomatic medications, nonadherence to treatment and comorbid conditions that limit the use of anti-migraine medications.

Areas covered: This critical perspective addresses the diagnosis and management of patients with RM. It also highlights the best practices tailored to this complex condition, serving as a valuable tool for physicians.

Expert opinion: Management demands specialized, holistic approach that considers patient preferences and may deviate from conventional evidence-based practices. Diagnosis requires thorough evaluation to exclude conditions like cluster headaches or trigeminal neuralgias. Treatment integrates symptomatic, interim, and prophylactic strategies. Symptomatic options include triptans, ditans, and gepants, often combined with NSAIDs or antiemetics, but gepants are first-line option because of their low risk for medication overuse headache. Interim treatments, intended to bridge to prophylactic therapy, might involve steroids or long acting triptans. Prophylactic treatments favor migraine-specific medications due to their superior tolerability and effectiveness. Non-pharmacological approaches are also encouraged while continuous monitoring and reassessment after initial treatments are essential, recognizing that RM may recur after a temporary improvement phase.

成人难治性偏头痛的管理步骤。
难治性偏头痛(RM)的特点是对偏头痛特异性治疗和重新定位治疗缺乏反应,严重影响生活质量。RM的危险因素包括过度使用对症药物、不坚持治疗以及限制使用抗偏头痛药物的合并症。涵盖领域:这个关键的观点解决了RM患者的诊断和管理。它还强调了针对这种复杂情况量身定制的最佳实践,作为医生的宝贵工具。专家意见:管理需要专门的、全面的方法,考虑到患者的喜好,可能会偏离传统的循证实践。诊断需要彻底的评估,以排除集束性头痛或三叉神经痛等病症。治疗综合了对症、中期和预防策略。有症状的选择包括曲坦类药物、地坦类药物和止吐药,通常与非甾体抗炎药或止吐药联合使用,但止吐药是一线选择,因为它们药物过度使用导致头痛的风险较低。作为预防治疗的过渡治疗,可能包括类固醇或长效曲坦类药物。预防性治疗倾向于偏头痛特异性药物,因为它们具有更好的耐受性和有效性。非药物治疗方法也被鼓励,但在初始治疗后持续监测和重新评估是必要的,认识到RM可能在短暂的改善阶段后复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Neurotherapeutics
Expert Review of Neurotherapeutics Medicine-Neurology (clinical)
CiteScore
7.00
自引率
2.30%
发文量
61
审稿时长
4-8 weeks
期刊介绍: Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信